Peter Haytaian compensation by year
Elevance Health Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $890,385 | $919,231 | $944,231 | $950,000 | $950,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $4,125,385 | $3,000,218 | $3,225,051 | $3,600,081 | $3,840,306 |
| Option awards | $1,374,662 | $999,871 | $1,074,976 | $1,199,997 | $1,199,710 |
| Non-equity incentive | $1,375,111 | $1,323,692 | $1,314,369 | $406,980 | $986,100 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $123,315 | $144,717 | $419,424 | $188,069 | $122,372 |
| Total | $7,888,858 | $6,387,729 | $6,978,051 | $6,345,127 | $7,098,488 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elevance Health, Inc. DEF 14A filed March 27, 2026, accession 0001156039-26-000031, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 11,483 | $4,025,366 | — |
| RSU | 8,268 | $2,898,347 | — |
| Option | 2,938 | — | $469.03 |
| Option | 6,187 | — | $499.11 |
| Option | 11,549 | — | $395.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Elevance Health, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Elevance Health discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $6,583,500 | $7,526,309 | $90,000 | $15,391,437 |
| Involuntary termination without cause | $4,180,000 | $4,802,184 | $60,000 | $10,065,286 |
| Retirement | $0 | $4,802,184 | $0 | $5,788,284 |
| Voluntary resignation | $0 | $4,802,184 | $0 | $5,788,284 |
| Death | $0 | $7,526,309 | $0 | $8,512,409 |
| Disability | $0 | $7,526,309 | $0 | $8,512,409 |
Per the Potential Payments Upon Termination or Change in Control table in Elevance Health, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Elevance Health’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Gail Boudreaux | President and Chief Executive Officer | $22,582,314 |
| Mark Kaye | Executive Vice President and Chief Financial Officer | $7,992,077 |
| Peter Haytaian · this page | Executive Vice President and President of Carelon and CarelonRx | $7,098,488 |
| Felicia Norwood | Executive Vice President and President of Government Health Benefits | $7,073,965 |
| C. Morgan Kendrick | Executive Vice President and President of Commercial and Specialty Health Benefits | $6,661,911 |
The full Elevance Health compensation record
free company briefThis page is one person within Elevance Health's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Elevance Health's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elevance Health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat